<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231231</url>
  </required_header>
  <id_info>
    <org_study_id>P04-5204</org_study_id>
    <nct_id>NCT00231231</nct_id>
  </id_info>
  <brief_title>Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)</brief_title>
  <official_title>Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the outcomes of stenting with distal&#xD;
      protection in the treatment of obstructive carotid artery disease during&#xD;
      peri-approval/initial commercialization in relation to the outcomes of the Sapphire Clinical&#xD;
      Trial. The devices to be utilized are the Cordis PRECISE Nitinol Stent Systems and the Cordis&#xD;
      ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of this study is a 30-day composite of major adverse clinical events (MAE) including any death, myocardial infarction, or stroke.</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <enrollment>1500</enrollment>
  <condition>Carotid Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>-PRECISE Nitinol Stent System (5F, 5.5F and 6F)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be &gt; 18 years of age.&#xD;
&#xD;
          2. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the&#xD;
             common or internal carotid artery and is clinically symptomatic; i.e., within the&#xD;
             previous 180 days has experienced symptoms in the ipsilateral carotid artery&#xD;
             distribution, defined as:&#xD;
&#xD;
               -  one or more TIAs, characterized by distinct focal neurologic dysfunction or&#xD;
                  monocular blindness with clearing of signs and symptoms within 24 hours, or&#xD;
&#xD;
               -  one or more completed strokes (as defined by this protocol) with persistence of&#xD;
                  symptoms or signs for more than 24 hours (the most recent event is used as the&#xD;
                  qualifying event), except as excluded below, with stenosis &gt;50%, (as determined&#xD;
                  by ultrasound or angiogram) of the common or internal carotid artery, OR The&#xD;
                  patient must have a &gt;80% diameter stenosis (as determined by ultrasound or&#xD;
                  angiogram) of the internal or common carotid artery without neurological&#xD;
                  symptoms.&#xD;
&#xD;
          3. To be entered into the study, the patient must have one or more of the following&#xD;
             conditions:&#xD;
&#xD;
             · congestive heart failure (class III/IV) and/or known severe left ventricular&#xD;
             dysfunction LVEF &lt; 30%&#xD;
&#xD;
               -  open heart surgery within six weeks&#xD;
&#xD;
               -  recent MI (&gt;24 hours and &lt;4 weeks)&#xD;
&#xD;
               -  unstable angina (CCS class III/IV)&#xD;
&#xD;
               -  synchronous severe cardiac and carotid disease requiring open heart surgery and&#xD;
                  carotid revascularization&#xD;
&#xD;
               -  severe pulmonary disease to include any of the following:&#xD;
&#xD;
          1. chronic oxygen therapy&#xD;
&#xD;
          2. resting PO2 of 60 mmHg&#xD;
&#xD;
          3. baseline hematocrit 50%&#xD;
&#xD;
          4. FEV1 or DLCO 50% of normal. · contralateral carotid occlusion · contralateral&#xD;
             laryngeal palsy · post-radiation treatment · previous CEA recurrent stenosis · high&#xD;
             cervical ICA lesions · CCA lesions below the clavicle · severe tandem lesions&#xD;
&#xD;
               -  abnormal stress test.&#xD;
&#xD;
        4. The qualifying ultrasound or angiogram was performed less than 30 days prior to study&#xD;
        entry.&#xD;
&#xD;
        · Stenosis &gt;50%: PSV&gt;130 cm/sec; EDV &lt;135 cm/sec&#xD;
&#xD;
        · Stenosis &gt;80%: PSV&gt;220 cm/sec; EDV &lt;135 cm/sec&#xD;
&#xD;
        · PSV ICA/PSV CCA ratio 4.0&#xD;
&#xD;
        5. The target vessel is in the native common or internal carotid artery. The arterial&#xD;
        segment to be treated has a diameter between 4 mm and 9 mm as the largest diameter either&#xD;
        proximal or distal to the lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient is experiencing an acute ischemic neurologic stroke or has experienced a&#xD;
             stroke within the past 48 hours.&#xD;
&#xD;
          2. There is any visual angiographic or ultrasound evidence of intraluminal thrombus&#xD;
             thought to increase the risk of plaque fragmentation and distal embolization.&#xD;
&#xD;
          3. There is total occlusion of the target carotid artery treatment site.&#xD;
&#xD;
          4. The reference segment diameter (distal common carotid and internal carotid artery&#xD;
             segment cephalic to the lesion) is less than 4mm or greater than 9mm. See Instructions&#xD;
             For Use, for proper stent sizing. The exception to this would be with a lesion having&#xD;
             &gt;95% stenosis where the true diameter of the distal vessel cannot be determined such&#xD;
             as the case with a string sign or distal vessel collapse. In this case the judgment of&#xD;
             the interventionalist will prevail with the intention not to oversize the stent to the&#xD;
             distal vessel by more than 2mm.&#xD;
&#xD;
          5. The patient has any intracranial aneurysm (&gt; 9 mm).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney A. Cohen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cordis Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Katzen BT, Criado FJ, Ramee SR, Massop DW, Hopkins LN, Donohoe D, Cohen SA, Mauri L; CASES-PMS Investigators. Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study. Catheter Cardiovasc Interv. 2007 Aug 1;70(2):316-23.</citation>
    <PMID>17630678</PMID>
  </results_reference>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>July 19, 2007</last_update_submitted>
  <last_update_submitted_qc>July 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

